Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Mar 26, 2024 8:37pm
98 Views
Post# 35954363

RE:ARBITRATION AWARD DATE VERSUS NEWS RELEASE DATE

RE:ARBITRATION AWARD DATE VERSUS NEWS RELEASE DATE
RPINVESTOR1 wrote: I found something interesting on the Internet. We all know that Andrew Schutte put out a News Release on November 16, 2023 announcing that Replicel Life Sciences had lost the Arbitration Case. 

A website (Jus Mundi) indicates that the decision was made on October 16, 2023 (See Award Date)!

https://jusmundi.com/en/document/decision/en-replicel-life-sciences-inc-v-shiseido-company-limited-representatives-of-the-parties-monday-18th-october-2021

If this is accurate, they left the shareholders twisting in the wind for a full month!


This is a very serious breach of the CSA rules regarding releasing material information related to a publicly traded companies in Canada:

"When must a publicly listed company make disclosures of material information?
The Disclosure rules state that material information is information about a company that has a significant effect, or would reasonably be expected to have a significant effect, on the market price of the company's securities. A company must disclose material information to the public immediately."

RPInvestor1 has found  material information regarding the Replicel vs Shiseido Arbitration judgement that was withheld for close to a month before releasing on Nov. 16th:
From Jus Mundi:
"Oct. 16th the Tribunal announced the dismissal of Replicel's claims finding that Shiseido validly terminated the Collaboration and Technology Transfer Agreement...."

 
 


<< Previous
Bullboard Posts
Next >>